Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.
A National Cancer Institute summit meeting on gastroenteropancreatic neuroendocrine and carcinoid tumors was held in September 2007 to present the currently accepted standards of care for patients with these tumors and to identify areas requiring investigation and development. These tumors are clinically and pathologically heterogeneous, present commonly with obscure symptoms that lead to delays in diagnosis of years, and have an incidence in the United States of 2.5 to 5 cases per 100,000. The 5-year survival rates range between 15% and 95%, depending on the site and extent of disease. This report delineates the main conclusions of the meeting, including the best practice diagnosis and treatment strategies for gastropancreatic neuroendocrine tumors, and the identification of clinical and scientific areas that are most in need of attention. The most pressing needs were public and physician education, identification of molecular markers for early diagnosis and therapeutic monitoring, improved imaging modalities and molecular prognostication, development of a standardized pathological classification system, and creation of regional centers of expertise with tumor and laboratory data banks. In addition, adequately validated neuroendocrine tumor models and cell lines should be established to investigate the molecular mechanisms involved in the control of their growth and secretion, and to facilitate the development of specific therapies that should be examined in well-designed multicenter studies of defined patient groups.
Modlin
Irvin M
IM
Department of Gastroenterological Surgery, Yale University School of Medicine, New Haven, CT 06520-8062, USA. imodlin@optonline.net
Moss
Steven F
SF
Chung
Daniel C
DC
Jensen
Robert T
RT
Snyderwine
Elizabeth
E
D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D035843:Biomedical Research / Q000592:standards / Q000639:trends*; D002276:Carcinoid Tumor / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy; D004195:Disease Models, Animal; D042241:Early Diagnosis; D005770:Gastrointestinal Neoplasms / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy; D006801:Humans; D015994:Incidence; D033183:Interdisciplinary Communication; D054547:National Cancer Institute (U.S.); D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000628:therapy; D015995:Prevalence; D011379:Prognosis; D012109:Research Support as Topic; D012307:Risk Factors; D018426:SEER Program; D015996:Survival Rate; D014481:United States / Q000453:epidemiology
D014408:Biomarkers, Tumor
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):705-15
16253895
Endocr Relat Cancer. 2003 Dec;10(4):437-50
14713256
Br J Cancer. 2006 Nov 6;95(9):1148-54
17031397
Gastroenterology. 2005 May;128(6):1717-51
15887161
Cancer Res. 2004 May 15;64(10):3687-93
15150129
Lancet. 1963 Feb 2;1(7275):238-9
14000847
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):753-81
16253899
Nature. 2007 Oct 25;449(7165):1003-7
17934449
Gut. 2001 Apr;48(4):536-41
11247899
Nat Genet. 1999 May;22(1):44-52
10319860
Circulation. 2005 Nov 22;112(21):3320-7
16286584
Yale J Biol Med. 1992 Nov-Dec;65(6):741-51; discussion 827-9
1341076
Cancer. 2005 Dec 1;104(11):2292-309
16258976
J Pathol. 1990 Apr;160(4):347-56
2358971
Cancer Res. 2003 Aug 15;63(16):4836-41
12941803
Cancer. 2002 Jan 15;94(2):331-43
11900219
Gastroenterology. 1991 Aug;101(2):303-11
1712329
N Engl J Med. 2007 Jan 4;356(1):6-9
17202450
Virchows Arch A Pathol Anat Histol. 1977 Apr 29;373(4):327-52
193245
Ann Oncol. 2006 Mar;17(3):461-6
16364959
Curr Opin Oncol. 2005 Jul;17(4):386-91
15933475
Mol Cell Biol. 2000 Aug;20(16):6147-58
10913196
World J Gastroenterol. 2007 Oct 21;13(39):5208-16
17876891
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29
17382268
Lancet Oncol. 2006 Sep;7(9):728-34
16945767
Virchows Arch. 2006 Oct;449(4):395-401
16967267
Gastroenterology. 1983 Nov;85(5):1120-30
6194039
Lancet. 1992 Oct 17;340(8825):930-2
1357347
J Clin Oncol. 2008 Sep 10;26(26):4311-8
18779618
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1118-23
11158604
Cancer. 2003 Feb 15;97(4):934-59
12569593
Virchows Arch. 2007 Oct;451(4):757-62
17674042
Circulation. 2005 Mar 29;111(12):1517-22
15781732
Lancet Oncol. 2008 Jan;9(1):61-72
18177818
Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):460-6
16437218
J Histochem Cytochem. 1969 May;17(5):303-13
4143745
N Engl J Med. 2006 Jul 20;355(3):270-80
16855267
Mol Cell Biol. 2004 Apr;24(8):3125-31
15060136
Gastroenterology. 2007 Mar;132(3):899-904
17383419